TY - JOUR
T1 - Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation
AU - on behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation
AU - Hiramoto, Nobuhiro
AU - Yamazaki, Hirohito
AU - Nakamura, Yukinori
AU - Uchida, Naoyuki
AU - Murata, Makoto
AU - Kondo, Tadakazu
AU - Yoshioka, Satoshi
AU - Eto, Tetsuya
AU - Nishikawa, Akinori
AU - Kimura, Takafumi
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Onishi, Yasushi
AU - Suzuki, Ritsuro
AU - Mori, Takehiko
N1 - Funding Information:
This study was supported in part by the Practical Research Project for Allergic Disease and Immunology (Research Technology of Medical Transplantation), Japan Agency for Medical Research and Development (AMED).
Funding Information:
We thank all physicians and data managers at the centers who contributed to gathering transplantation data from the TRUMP. We also appreciate the contribution of the members of the Data Management Committees of the Japan Society for Hematopoietic Cell Transplantation. On behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/1
Y1 - 2022/1
N2 - Thus far, there have been no large cohort studies on total body irradiation (TBI)-containing conditioning regimens without antithymocyte globulin (ATG) in adults with aplastic anemia (AA) undergoing umbilical cord blood (UCB) transplantation (UCBT). We retrospectively analyzed 115 adults with idiopathic AA undergoing UCBT using TBI-containing reduced-intensity conditioning (RIC) regimens without ATG between 2000 and 2018 on behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. We then compared transplantation outcomes between a fludarabine (Flu)- and melphalan (Mel)-based regimen (FM) and a Flu- and cyclophosphamide (Cy)-based regimen (FC). The median patient age at UCBT was 41 years. The median total nucleated cell and total CD34+ cell doses in a UCB unit at cryopreservation were 2.5 × 107/kg and 0.7 × 105/kg, respectively. The median follow-up period for survivors was 47 months. The cumulative incidence rate of neutrophil engraftment was 76.5%, and the 4-year overall survival (OS) rate was 64.3%. In multivariate analysis, the covariates that were significantly associated with a higher neutrophil engraftment were total CD34+ cell dose in an UCB unit (≥ 0.7 × 105/kg; hazard ratio, 0.57, P = 0.01) and total dose of TBI (4 Gy of TBI; hazard ratio, 0.32, P = 0.01). There was no significant difference in the cumulative incidence of neutrophil engraftment and the 4-year OS between the FM and FC groups. In conclusion, TBI-containing RIC regimens without ATG are suitable for adults with AA undergoing UCBT. There were no significant differences in transplantation outcomes between the FM and FC groups.
AB - Thus far, there have been no large cohort studies on total body irradiation (TBI)-containing conditioning regimens without antithymocyte globulin (ATG) in adults with aplastic anemia (AA) undergoing umbilical cord blood (UCB) transplantation (UCBT). We retrospectively analyzed 115 adults with idiopathic AA undergoing UCBT using TBI-containing reduced-intensity conditioning (RIC) regimens without ATG between 2000 and 2018 on behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. We then compared transplantation outcomes between a fludarabine (Flu)- and melphalan (Mel)-based regimen (FM) and a Flu- and cyclophosphamide (Cy)-based regimen (FC). The median patient age at UCBT was 41 years. The median total nucleated cell and total CD34+ cell doses in a UCB unit at cryopreservation were 2.5 × 107/kg and 0.7 × 105/kg, respectively. The median follow-up period for survivors was 47 months. The cumulative incidence rate of neutrophil engraftment was 76.5%, and the 4-year overall survival (OS) rate was 64.3%. In multivariate analysis, the covariates that were significantly associated with a higher neutrophil engraftment were total CD34+ cell dose in an UCB unit (≥ 0.7 × 105/kg; hazard ratio, 0.57, P = 0.01) and total dose of TBI (4 Gy of TBI; hazard ratio, 0.32, P = 0.01). There was no significant difference in the cumulative incidence of neutrophil engraftment and the 4-year OS between the FM and FC groups. In conclusion, TBI-containing RIC regimens without ATG are suitable for adults with AA undergoing UCBT. There were no significant differences in transplantation outcomes between the FM and FC groups.
KW - Antithymocyte globulin
KW - Aplastic anemia
KW - Cord blood transplantation
KW - Total body irradiation
UR - http://www.scopus.com/inward/record.url?scp=85115641595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115641595&partnerID=8YFLogxK
U2 - 10.1007/s00277-021-04664-z
DO - 10.1007/s00277-021-04664-z
M3 - Article
C2 - 34546409
AN - SCOPUS:85115641595
VL - 101
SP - 165
EP - 175
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 1
ER -